The Modulatory Effect of 15d-PGJ2 in Dendritic Cells

T. S. Farnesi-de-Assunção, Vanessa Carregaro, Carlos Silva, Antonio José de Pinho, M. Napimoga
{"title":"The Modulatory Effect of 15d-PGJ2 in Dendritic Cells","authors":"T. S. Farnesi-de-Assunção, Vanessa Carregaro, Carlos Silva, Antonio José de Pinho, M. Napimoga","doi":"10.11131/2014/101083","DOIUrl":null,"url":null,"abstract":"The PPAR-γ ligands, in special 15-deoxy-Δ12,14-PGJ2 (15d-PGJ2), negatively regulate the cells of innate and adaptative immune system and present excellent results in different models of inflammatory diseases. These findings support the notion that PPAR-γ ligands may be used as therapeutic agents in different diseases. Although PPAR-γ is expressed in different cells and tissues including dendritic cells (DC), few studies have evaluated the effects of these ligands on DCs. Thus, in this study we evaluated the effect of 15d-PGJ2 on DC surface molecule expression, including MHC-II, CD80, and CD86. In addition, we quantified cytokine production in the presence of 15d-PGJ2 or rosiglitazone. Expression of the surface molecules was measured by flow cytometry and cytokines production was measured by ELISA in supernatant of BMDC cultures. The results suggest that 15d-PGJ2 reduced the expression of costimulatory molecules (CD80 and CD86), without altering MCH-class II expression. Furthermore the natural PPAR-γ agonist significantly reduced levels of proinflammatory cytokines (IL-12, IFN-γ, and TNF-α) and appears to also reduce IL-1β levels. Rosiglitazone reduced the expression of these cytokines albeit to a lesser extent. These data suggest the idea that 15d-PGJ2 could be a therapeutic strategy in diseases where DCs play a crucial role, due to its ability to reduce costimulatory molecules expression and modulate the inflammatory environment.","PeriodicalId":30720,"journal":{"name":"Nuclear Receptor Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2014-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear Receptor Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11131/2014/101083","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

The PPAR-γ ligands, in special 15-deoxy-Δ12,14-PGJ2 (15d-PGJ2), negatively regulate the cells of innate and adaptative immune system and present excellent results in different models of inflammatory diseases. These findings support the notion that PPAR-γ ligands may be used as therapeutic agents in different diseases. Although PPAR-γ is expressed in different cells and tissues including dendritic cells (DC), few studies have evaluated the effects of these ligands on DCs. Thus, in this study we evaluated the effect of 15d-PGJ2 on DC surface molecule expression, including MHC-II, CD80, and CD86. In addition, we quantified cytokine production in the presence of 15d-PGJ2 or rosiglitazone. Expression of the surface molecules was measured by flow cytometry and cytokines production was measured by ELISA in supernatant of BMDC cultures. The results suggest that 15d-PGJ2 reduced the expression of costimulatory molecules (CD80 and CD86), without altering MCH-class II expression. Furthermore the natural PPAR-γ agonist significantly reduced levels of proinflammatory cytokines (IL-12, IFN-γ, and TNF-α) and appears to also reduce IL-1β levels. Rosiglitazone reduced the expression of these cytokines albeit to a lesser extent. These data suggest the idea that 15d-PGJ2 could be a therapeutic strategy in diseases where DCs play a crucial role, due to its ability to reduce costimulatory molecules expression and modulate the inflammatory environment.
15d-PGJ2在树突状细胞中的调节作用
PPAR-γ配体,在特殊的15-脱氧-Δ12,14-PGJ2 (15d-PGJ2)中,负向调节先天和适应性免疫系统的细胞,并在不同的炎症疾病模型中表现出优异的效果。这些发现支持PPAR-γ配体可作为不同疾病的治疗剂的观点。尽管PPAR-γ在包括树突状细胞(DC)在内的不同细胞和组织中表达,但很少有研究评估这些配体对树突状细胞的影响。因此,在本研究中,我们评估了15d-PGJ2对DC表面分子表达的影响,包括MHC-II、CD80和CD86。此外,我们量化了15d-PGJ2或罗格列酮存在时细胞因子的产生。流式细胞术检测表面分子的表达,ELISA法检测细胞因子的产生。结果表明,15d-PGJ2降低了共刺激分子(CD80和CD86)的表达,但未改变mch - II类的表达。此外,天然PPAR-γ激动剂显著降低促炎细胞因子(IL-12, IFN-γ和TNF-α)水平,似乎也降低IL-1β水平。罗格列酮降低了这些细胞因子的表达,尽管程度较轻。这些数据表明,15d-PGJ2可能是dc发挥关键作用的疾病的治疗策略,因为它能够减少共刺激分子的表达并调节炎症环境。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信